Skip to main content
. 2019 Dec;11(12):5440–5452. doi: 10.21037/jtd.2019.11.45

Table 2. Initial medication after HTX.

Parameter PPM (n=36) No PPM (n=585) Difference 95% CI P value
Cyclosporine A, n (%) 22 (61.1) 322 (55.0) 6.1 −10.3–22.5 0.48
Tacrolimus, n (%) 14 (38.9) 263 (45.0) 6.1 −10.3–22.5 0.48
Azathioprine, n (%) 19 (52.8) 245 (41.9) 10.9 −5.9–27.7 0.20
Mycophenolate mofetil, n (%) 17 (47.2) 340 (58.1) 10.9 −5.9–27.7 0.20
Steroids, n (%) 36 (100.0) 585 (100.0) 0.0 NA NA
Acetylsalicylic acid, n (%) 3 (8.3) 61 (10.4) 2.1 −7.3–11.5 0.69
Beta blocker, n (%) 6 (16.7) 106 (18.1) 1.4 −11.2–14.0 0.83
Ivabradine, n (%) 2 (5.6) 52 (8.9) 3.3 −4.5–11.1 0.49
Calcium channel blocker 12 (33.3) 153 (26.2) 7.1 −8.7–22.9 0.34
ACE inhibitor/sartan, n (%) 18 (50.0) 256 (43.8) 6.2 −10.6–23.0 0.46
Diuretic, n (%) 36 (100.0) 585 (100.0) 0.0 NA NA
Statin, n (%) 11 (30.6) 228 (39.0) 8.4 −7.2–24.0 0.31
Gastric protection (PPI/H2 blocker), n (%) 36 (100.0) 585 (100.0) 0.0 NA NA

ACE inhibitor, angiotensin-converting-enzyme inhibitor; CI, confidence Interval; HTX, heart transplantation; H2 blocker, histamine receptor blocker; n, number; NA, not applicable; PPI, proton pump inhibitor; PPM, permanent pacemaker.